Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia

British Journal of Haematology

Volumn 154, Issue 2, 2011, Pages 223-228

  Treon, Steven P ^a,b   Yang, Guang ^a,b   Hanzis, Christine ^a   Ioakimidis, Leukothea ^a   Verselis, Sigitas J ^a   Fox, Edward A ^a,b   Xu, Lian ^a   Hunter, Zachary R ^a   Tseng, Hsiuyi ^a   Manning, Robert J ^a   Patterson, Christopher J ^a   Sheehy, Patricia ^a   Turnbull, Barry ^c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BioBridges   (United States)

Author keywords

Complete response; FCGR3A; Rituximab; Very good partial response; Waldenstrom macroglobulinemia

Indexed keywords

BETA 2 MICROGLOBULIN; BORTEZOMIB; CYCLOPHOSPHAMIDE; FLUDARABINE; IMMUNOGLOBULIN M; IMMUNOMODULATING AGENT; RITUXIMAB;

ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DNA POLYMORPHISM; FCGR2A GENE; FCGR2B GENE; FCGR3A GENE; GENE; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEMATOCRIT; HUMAN; HUMAN CELL; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; THROMBOCYTE COUNT; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; RECEPTORS, IGG; TREATMENT OUTCOME; WALDENSTROM MACROGLOBULINEMIA;

EID: 79959814926     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08726.x     Document Type: Article

References (45)

1. Anolik, J.H., Campbell, D., Felgar, R.E., Young, F., Sanz, I., Rosenblatt, J. & Looney, R.J. (2003) The relationship of Fcgamma RIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis and Rheumatism, 48, 455-459.
2. Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P. & Watier, H. (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood, 99, 754-758.
3. Dhodapkar, M.V., Hoering, A., Gertz, M.A., Rivkin, S., Szymonifka, J., Crowley, J. & Barlogie, B. (2009) Long term survival in Waldenstrom Macroglobulinaemia: 10year follow-up of Southwest Oncology Group-directed intergroup trial S9003. Blood, 113, 793-796.
4. Dimopoulos, M.A., Alexanian, R., Gika, D., Anagnostopoulos, A., Zervas, C., Zomas, A., Kyrtsonis, M.C., Anagnostopoulos, N., Pangalis, G.A. & Weber, D.M. (2004) Treatment of Waldenstrom's Macroglobulinaemia with rituximab: prognostic factors for response and progression. Leukemia and Lymphoma, 45, 2057-2061.
5. Dimopoulos, M.A., Anagnostopoulos, A., Zervas, C., Kyrtsonis, M.C., Zomas, A., Bourantas, C., Anagnostopoulos, N. & Pangalis, G. (2005) Predictive factors for response to rituximab in Waldenstrom's Macroglobulinaemia. Clinical Lymphoma, 5, 270-272.
6. Dimopoulos, M.A., Kastritis, E., Delimpassi, S., Zomas, A., Kyrtsonis, M.C. & Zervas, K. (2008) The International Prognostic Scoring System for Waldenstrom's Macroglobulinema is applicable in patients treated with rituximab-based regimens. Haematologica, 93, 1420-1423.
7. Dimopoulos, M.A., Gertz, M.A., Kastritis, E., Garcia-Sanz, R., Kimby, E.K., Leblond, V., Fermand, J.P., Merlini, G., Morel, P., Morra, E., Ocio, E.M., Owen, R., Ghobrial, I.M., Seymour, J., Kyle, R.A. & Treon, S.P. (2009) Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinaemia. Journal of Clinical Oncology, 27, 120-126.
8. Gertz, M.A., Abonour, R., Heffner, L.T., Greipp, P.R., Uno, H. & Rajkumar, S.V. (2009) Clinical value of minor responses after 4 doses of rituximab in Waldenstrom's Macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial. British Journal of Haematology, 147, 677-680.
9. Grundy, H.O., Peltz, G., Moore, K.W., Golbus, M.S., Jackson, L.G. & Lebo, R.V. (1989) The polymorphic Fc gamma receptor II gene maps to human chromosome 1q. Immunogenetics, 29, 331-339.
10. de Haas, M., Koene, H.R., Kleijer, M., de Vries, E., Simsek, S., van Tol, M.J., Roos, D. & von dem Borne, A.E. (1996) A triallelic Fc gamma receptor type IIIA polymorphism influences the binding of human IgG by NK cell Fc gamma RIIIa. Journal of Immunology, 156, 3948-3955.
11. Hatjiharissi, E., Hansen, M., Santos, D.D., Xu, L., Leleu, X., Dimmock, E.W., Ho, A.W., Hunter, Z.R., Branagan, A.R., Patterson, C.J., Kortsaris, A., Verselis, S., Fox, E. & Treon, S.P. (2007) Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy. Clinical Lymphoma & Myeloma, 7, 286-290.
12. Ioakimidis, L., Patterson, C.J., Hunter, Z.R., Soumerai, J.D., Manning, R.J., Turnbull, B., Sheehy, P. & Treon, S.P. (2009) Comparative outcomes following CP-R, CVP-R and CHOP-R in Waldenstrom's Macroglobulinaemia. Clinical Lymphoma & Myeloma, 9, 62-66.
13. Kimby, E., Treon, S.P., Anagnostopoulos, A., Dimopoulos, M., Garcia-Sanz, R., Gertz, M.A., Johnson, S., LeBlond, V., Fermand, J.P., Maloney, D.G., Merlini, G., Morel, P., Morra, E., Nichols, G., Ocio, E.M., Owen, R., Stone, M. & Bladé, J. (2006) Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinaemia. Clinical Lymphoma & Myeloma, 6, 380-383.
14. Koene, H.R., Kleijer, M., Algra, J., Roos, D., von dem Borne, A.E. & de Haas, M. (1997) Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood, 90, 1109-1114.
15. Kyriakou, C., Canals, C., Sibon, D., Cahn, J.Y., Kazmi, M., Arcese, W., Kolbe, K., Gorin, N.C., Thomson, K., Milpied, N., Niederwieser, D., Indrák, K., Corradini, P., Sureda, A. & Schmitz, N. (2010) High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinaemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology, 28, 2227-2232.
16. Lahuerta, J.J., Mateos, M.V., Martínez-López, J., Rosiñol, L., Sureda, A., de la Rubia, J., García-Laraña, J., Martínez-Martínez, R., Hernández-García, M.T., Carrera, D., Besalduch, J., de Arriba, F., Ribera, J.M., Escoda, L., Hernández-Ruiz, B., García-Frade, J., Rivas-González, C., Alegre, A., Bladé, J. & San Miguel, J.F. (2008) Influence of pre- and post- transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. Journal of Clinical Oncology, 26, 5775-5782.
17. Laszlo, D., Andreola, G., Rigacci, L., Fabbri, A., Rabascio, C., Mancuso, P., Pruneri, G., Radice, D., Pinto, A., Frigeri, F., Calabrese, L., Billio, A., Bertolini, F. & Martinelli, G. (2010) Rituximab and subcutaneous 2-chloro-2'-deoxadenosine combination treatment for patients with Waldenstrom Macroglobulinaemia: clinical and biologic results of a phase II multicenter study. Journal of Clinical Oncology, 28, 2233-2238.
18. Lejeune, J., Thibault, G., Ternant, D., Cartron, G., Watier, H. & Ohresser, M. (2008) Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodies. Journal of Clinical Oncology, 26, 5489-5491.
19. Manches, O., Lui, G., Chaperot, L., Gressin, R., Molens, J.P., Jacob, M.C., Sotto, J.J., Leroux, D., Bensa, J.C. & Plumas, J. (2003) In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood, 101, 949-954.
20. Moreau, P., Attal, M., Pégourié, B., Planche, L., Hulin, C., Facon, T., Stoppa, A.M., Fuzibet, J.G., Grosbois, B., Doyen, C., Ketterer, N., Sebban, C., Kolb, B., Chaleteix, C., Dib, M., Voillat, L., Fontan, J., Garderet, L., Jaubert, J., Mathiot, C., Esseltine, D., Avet-Loiseau, H. & Harousseau, J.L. (2011) Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. Blood, 117, 3041-3044.
21. Morel, P., Duhamel, A., Gobbi, P., Dimopoulos, M.A., Dhodapkar, M.V., McCoy, J., Crowley, J., Ocio, E.M., Garcia-Sanz, R., Treon, S.P., Leblond, V., Kyle, R.A., Barlogie, B. & Merlini, G. (2009) International prognostic scoring system for Waldenstrom Macroglobulinaemia. Blood, 113, 4163-4170.
22. Morschhauser, F., Radford, J., Van Hoof, A., Vitolo, U., Soubeyran, P., Tilly, H., Huijgens, P.C., Kolstad, A., d'Amore, F., Gonzalez Diaz, M., Petrini, M., Sebban, C., Zinzani, P.L., van Oers, M.H., van Putten, W., Bischof-Delaloye, A., Rohatiner, A., Salles, G., Kuhlmann, J. & Hagenbeek, A. (2008) Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. Journal of Clinical Oncology, 26, 5156-5164.
23. Mössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C., Nopora, A., van Puijenbroek, E., Ferrara, C., Sondermann, P., Jäger, C., Strein, P., Fertig, G., Friess, T., Schüll, C., Bauer, S., Dal Porto, J., Del Nagro, C., Dabbagh, K., Dyer, M.J., Poppema, S., Klein, C. & Umaña, P. (2010) Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood, 115, 4393-4402.
24. Paiva, M., Marques, H., Martins, A., Ferreira, P., Catarino, R. & Medeiros, R. (2008) FcgammaRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients. Cancer Genetics Cytogenetics, 183, 35-40.
25. Parren, P.W., Warmerdam, P.A., Boeije, L.C., Arts, J., Westerdaal, N.A., Vlug, A., Capel, P.J., Aarden, L.A. & van de Winkel, J.G. (1992) On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. Journal of Clinical Investigation, 90, 1537-1546.
26. Persky, D.O., Dornan, D., Goldman, B.H., Braziel, R.M., Fisher, R.I., LeBlanc, M., Maloney, D.G., Miller, T.P., Press, O.W. & Rimsza, L.M. (2009) Fc gamma receptor 3A genotype predicts overall survival for follicular lymphoma patients treated on Southwest Oncology Group Trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. Blood (ASH Meeting Abstracts), 114, 51, Abstract 111.
27. Pierz, K., Gu, S., Lewis, M., Schmitz, S.F., Falandry, C., Salles, G., Fey, M., Martinelli, G., Hitz, F. & Ghielmini, M. (2010) Predictive value of FCGR3A genotype on response to rituximab induction and maintenance therapy in follicular non-Hodgkin's lymphoma. Journal of Clinical Oncology (ASCO Meeting Abstracts), 28, 15s, Abstract 8065.
28. Ravetch, J.V. & Bolland, S. (2001) IgG Fc receptors. Annual Review of Immunology, 19, 275-290.
29. Salles, G., Morschhauser, F., Cartron, G., Lamy, T., Milpied, N.J., Thieblemont, C., Tilly, H., Birkett, T. & Burgess, M. (2008) A phase I/II study of RO5072759 (GA101) in patients with relapsed/refractory CD20+ malignant disease. Blood (ASH Meeting Abstracts), 112, 93, Abstract 234.
30. Treon, S.P. (2009) How I treat Waldenstrom macroglobulinaemia. Blood, 114, 2375-2385.
31. Treon, S.P., Hansen, M., Branagan, A.R., Verselis, S., Emmanouilides, C., Kimby, E., Frankel, S.R., Touroutoglou, N., Turnbull, B., Anderson, K.C., Maloney, D.G. & Fox, E.A. (2005a) Polymorphisms in FcRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's Macroglobulinaemia. Journal of Clinical Oncology, 23, 474-481.
32. Treon, S.P., Emmanouilides, C., Kimby, E., Kelliher, A., Preffer, F., Branagan, A.R., Anderson, K.C., Frankel, S.R. & Waldenström's Macroglobulinemia Clinical Trials Group. (2005b) Extended rituximab therapy in Waldenstrom's Macroglobulinaemia. Annals of Oncology, 16, 132-138.
33. Treon, S.P., Soumerai, J.D., Branagan, A.R., Hunter, Z.R., Patterson, C.J., Ioakimidis, L., Briccetti, F.M., Pasmantier, M., Zimbler, H., Cooper, R.B., Moore, M., Hill, 2nd, J., Rauch, A., Garbo, L., Chu, L., Chua, C., Nantel, S.H., Lovett, D.R., Boedeker, H., Sonneborn, H., Howard, J., Musto, P., Ciccarelli, B.T., Hatjiharissi, E. & Anderson, K.C. (2008a) Thalidomide and rituximab in Waldenstrom's macroglobulinaemia. Blood, 112, 4452-4457.
34. Treon, S.P., Soumerai, J.D., Branagan, A.R., Hunter, Z.R., Patterson, C.J., Ioakimidis, L., Chu, L., Musto, P., Baron, A.D., Nunnink, J.C., Kash, J.J., Terjanian, T.O., Hyman, P.M., Nawfel, E.L., Sharon, D.J., Munshi, N.C. & Anderson, K.C. (2008b) Lenalidomide and rituximab in Waldenstrom's macroglobulinaemia. Clinical Cancer Research, 15, 355-360.
35. Treon, S.P., Branagan, A.R., Ioakimidis, L., Soumerai, J.D., Patterson, C.J., Turnbull, B., Wasi, P., Emmanouilides, C., Frankel, S.R., Lister, A., Morel, P., Matous, J., Gregory, S.A. & Kimby, E. (2009a) Long term outcomes to fludarabine and rituximab in Waldenstrom's macroglobulinaemia. Blood, 113, 3673-3678.
36. Treon, S.P., Ioakimidis, L., Soumerai, J.D., Patterson, C.J., Sheehy, P., Nelson, M., Willen, M., Matous, J., Mattern, 2nd, J., Diener, J.G., Keogh, G.P., Myers, T.J., Boral, A., Birner, A., Esseltine, D.L. & Ghobrial, I.M. (2009b) Primary therapy of Waldenstrom's Macroglobulinaemia with bortezomib, dexamethasone and rituximab: results of WMCTG clinical trial 05-180. Journal of Clinical Oncology, 27, 3830-3835.
37. Treon, S.P., Hanzis, C., Manning, R., Ioakimidis, L., Patterson, C.J., Hunter, Z.R., Turnbull, B. & Sheehy, P. (2009c) Maintenance rituximab is associated with improved progression free and overall survival in Waldenstrom's macroglobulinaemia. Blood, 114, 1443, Abstract 3750.
38. Wang, M., Delasalle, K., Feng, L., Thomas, S., Giralt, S., Qazilbash, M., Handy, B., Lee, J.J. & Alexanian, R. (2010) CR represents an early index of potential long survival in multiple myeloma. Bone Marrow Transplantation, 45, 498-504.
39. Warmerdam, P.A., van de Winkel, J.G., Gosselin, E.J. & Capel, P.J. (1990) Molecular basis for a polymorphism of human Fc gamma receptor II (CD32). Journal of Experimental Medicine, 172, 19-25.
40. Warmerdam, P.A., van de Winkel, J.G., Vlug, A., Westerdaal, N.A. & Capel, P.J. (1991) A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. Journal of Immunology, 147, 1338-1343.
41. Weng, W.K. & Levy, R. (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. Journal of Clinical Oncology, 21, 3940-3947.
42. Weng, W.K. & Levy, R. (2009) Genetic polymorphism of the inhibitory IgG Fc receptor FcγRIIb is not associated with clinical outcome of rituximab treated follicular lymphoma patients. Leukemia and Lymphoma, 50, 723-727.
43. de Wit, T.P., Suijkerbuijk, R.F., Capel, P.J., van Kessel, A.G. & van de Winkel, J.G. (1993) Assignment of three human high-affinity Fc gamma receptor I genes to chromosome 1, band q21.1. Immunogenetics, 38, 57-59.
44. Wu, J., Edberg, J.C., Redecha, P.B., Bansal, V., Guyre, P.M., Coleman, K., Salmon, J.E. & Kimberly, R.P. (1997) A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. Journal of Clinical Investigations, 100, 1059-1070.
45. Yang, G., Gong, P., Xu, L., Hunter, Z.R., Zhou, Y., Liu, X., Cao, Y., Ciccarelli, B., Patterson, C.J. & Treon, S.P. (2010) Activity of the CD20-directed monoclonal antibody GA101 relative to rituximab in Waldenstrom's macroglobulinaemia (WM), and applicability to patients expressing FcγRIIIA-158F/F. Journal of Clinical Oncology (ASCO Meeting Abstracts), 28, 15s, Abstract 8112.